MedTrace Logo

A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia

NCT06525636 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-11-14

No results posted yet for this study

Summary

A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.

Conditions

  • X-linked Hypophosphatemia

Interventions

DRUG

KK8123

Subcutaneous administration

Sponsors & Collaborators

  • Kyowa Kirin, Inc.

    collaborator INDUSTRY

  • Kyowa Kirin Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Kyowa Kirin · Kyowa Kirin, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-09
Primary Completion
2028-02-11
Completion
2028-05-10
FDA Drug
Yes

Countries

  • United States
  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06525636 on ClinicalTrials.gov